Intellia Therapeutics Inc
NASDAQ:NTLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
US |
|
H
|
Hoegh Autoliners ASA
OSE:HAUTO
|
NO |
|
Fresnillo PLC
LSE:FRES
|
MX |
|
Peach Property Group AG
SIX:PEAN
|
CH |
|
Pharol SGPS SA
OTC:PHRZF
|
PT |
|
Enterprise Financial Services Corp
NASDAQ:EFSC
|
US |
|
Remgro Ltd
OTC:RMGOF
|
ZA |
|
L
|
Lgi Ltd
ASX:LGI
|
AU |
|
Tesmec SpA
MIL:TES
|
IT |
|
Obsidian Energy Ltd
TSX:OBE
|
CA |
|
P
|
Procter & Gamble Co
DUS:PRG
|
US |
|
Privia Health Group Inc
NASDAQ:PRVA
|
US |
|
S-Oil Corp
KRX:010950
|
KR |
Wall St Price Targets
NTLA Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
NTLA is 26.469 USD with a low forecast of 5.05 USD and a high forecast of 99.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NTLA's stock price target?
Price Target
26.469
USD
According to Wall Street analysts, the average 1-year price target for
NTLA is 26.469 USD with a low forecast of 5.05 USD and a high forecast of 99.75 USD.
What is the Revenue forecast for Intellia Therapeutics Inc?
Projected CAGR
51%
Over the last 10 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 8 years is 51%.